2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Renal Cell
11
Colorectal Neoplasms
4
Breast Neoplasms
3
Solid Tumors
2
Sarcoma
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Gastrointestinal Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Bile Duct Neoplasms
2
Vulvar Neoplasms
1
Triple Negative Breast Neoplasms
1
Recurrence
1
Neuroendocrine Tumors
1
Neoplasms
1
Liver Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Glioblastoma
1
Gallbladder Neoplasms
1
Disease Progression
1
Disease
1
Clear-cell metastatic renal cell carcinoma
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Neuroendocrine
1
Carcinoma, Hepatocellular
1
Advanced Solid Tumors
1
Advanced Adult Hepatocellular Carcinoma
1
Interventions
Cyclophosphamide
153
Dexamethasone
141
Rituximab
85
fludarabine
79
Lenalidomide
72
Cytarabine
70
Bortezomib
64
fludarabine phosphate
63
Gemcitabine
62
venetoclax
54
Etoposide
53
pomalidomide
52
pembrolizumab
52
Paclitaxel
48
Cisplatin
48
Carboplatin
48
Peripheral Blood Stem Cell Transplantation
47
Filgrastim
40
Radiotherapy
39
Busulfan
37
Calcium Dobesilate
36
Methotrexate
34
Melphalan
34
Bevacizumab
33
carfilzomib
32
Cyclosporine
32
Azacitidine
32
Mycophenolic Acid
30
Vincristine
29
Bendamustine Hydrochloride
29
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
tivozanib
×
Clear all
NCT01853644
2021-10-12
TIVO
Northwestern University
Phase 2
Completed
31 enrolled
12 charts